Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 12Neoplasms 10Multiple Myeloma 8Prostatic Neoplasms 6Neoplasm Metastasis 5Giant Cell Tumor of Bone 5Fractures, Bone 4Recurrence 3Osteoporosis 3Bone Neoplasms 3Bone Diseases, Metabolic 3Spinal Cord Compression 2Smoldering Multiple Myeloma 2Parathyroid Neoplasms 2Lymphoma 2Kidney Neoplasms 2Giant Cell Tumors 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Thyroid Neoplasms 1Paraproteinemias 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplastic Processes 1Neoplasms, Plasma Cell 1Multiple Endocrine Neoplasia Type 1 1Melanoma 1Mastocytosis, Systemic 1Lymphoma, Non-Hodgkin 1

Interventions

Denosumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Castrate-resistant Prostate Cancer × Denosumab × Clear all
NCT01824342 2015-03-05

Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer

Amgen

Phase 3 Completed
18 enrolled 13 charts
Genitourinary

Castrate-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡